Biotech Archives - Page 4 of 733

1 minute read

Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies

June 17, 10:53 AM

Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and fatigue were observed.

MIRM

2 minute read

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

By Vandana Singh

June 17, 9:21 AM

Mustang Bio shares soar 190.9% on high trading volume as Phase 1/2 trial data for CAR T-cell therapy MB-106 shows positive results.

FBIO

2 minute read

Marinus Pharmaceuticals Shares Mixed Results From IV Formulated Ganaxolone In Pretreated Seizure Patients

By Vandana Singh

June 17, 9:14 AM

Marinus Pharmaceuticals announces Phase 3 RAISE trial results for IV ganaxolone in refractory status epilepticus.

MRNS

1 minute read

Philips Zenition 90 Motorized Receives FDA 510(k) Clearance To Help Clinicians Deliver High Quality Care With A High-Powered And Fast Motorized Mobile C-Arm

By Benzinga Newsdesk

June 17, 9:05 AM

Intuitive motorization for greater control and high-power (25 kW [1]) for state-of-the-art image quality supports complex vascular needs and a full range of clinical proceduresAutomated workflows contribute to greater

PHG

2 minute read

What’s Going On With Ovid Therapeutics After Takeda’s Two Phase 3 Epilepsy Studies Fail?

By Vandana Singh

June 17, 8:58 AM

Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.

OVID

2 minute read

Japan Pharma Giant Takeda’s Anti-Seizure Treatment Flunks In Two Late-Stage Studies

By Vandana Singh

June 17, 8:41 AM

Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet and Lennox-Gastaut syndromes

TAK

1 minute read

Evoke Pharma Reports Commercial Strategy Progress & Momentum For GIMOTI; Announced The Promotion Of Mark Kowieski To The Role Of Chief Financial Officer In May 2024

By Benzinga Newsdesk

June 17, 8:41 AM

Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024Promoted former VP of Finance, Mark Kowieski to Chief Financial OfficerSOLANA BEACH, Calif., June 17, 2024

EVOK

1 minute read

Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative To Improve Quality Of Care Through Identification, Dissemination, And Implementation Of Best Practices For The Diagnosis And Management Of Recur…

By Benzinga Newsdesk

June 17, 8:37 AM

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative activities and

KNSA

1 minute read

BioMarin Presents Data Highlighting Impact Of VOXZOGO In Bone Health And Health-Related Quality Of Life In Achondroplasia At 2024 ICCBH

By Benzinga Newsdesk

June 17, 8:34 AM

New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of Observation in Children with AchondroplasiaPhase 2 and 3 Data on VOXZOGO Demonstrate Safety,

BMRN

1 minute read

Mirum’s Volixibat Achieves Interim Analyses In VANTAGE PBC And VISTAS PSC Studies; Showed 3.8 Point Reduction From Baseline And 2.3 Point Placebo-Adjusted Reduction In Primary Endpoint Of Pruritus

By Benzinga Newsdesk

June 17, 8:11 AM

- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus- VISTAS PSC interim analysis exceeds efficacy threshold for study

MIRM